Concepts (240)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 13 | 2021 | 217 | 3.500 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 87 | 1.990 |
Why?
|
| Hyponatremia | 3 | 2023 | 8 | 1.990 |
Why?
|
| Child | 25 | 2023 | 1228 | 1.890 |
Why?
|
| Kidney Transplantation | 4 | 2022 | 118 | 1.560 |
Why?
|
| Kidney Failure, Chronic | 4 | 2019 | 150 | 1.530 |
Why?
|
| Sodium | 5 | 2023 | 60 | 1.490 |
Why?
|
| Acute Kidney Injury | 4 | 2021 | 40 | 1.430 |
Why?
|
| Humans | 50 | 2023 | 26010 | 1.200 |
Why?
|
| Nephrotic Syndrome | 2 | 2022 | 25 | 1.150 |
Why?
|
| Adolescent | 20 | 2021 | 2064 | 1.140 |
Why?
|
| Hypercalcemia | 2 | 2022 | 10 | 1.120 |
Why?
|
| Hydronephrosis | 2 | 2019 | 6 | 1.090 |
Why?
|
| Alkalosis | 2 | 2023 | 2 | 1.060 |
Why?
|
| Allopurinol | 2 | 2018 | 5 | 1.060 |
Why?
|
| Hyperkalemia | 2 | 2022 | 6 | 1.060 |
Why?
|
| Potassium | 3 | 2022 | 63 | 1.030 |
Why?
|
| Albuminuria | 4 | 2007 | 14 | 1.030 |
Why?
|
| Prospective Studies | 12 | 2023 | 1658 | 1.010 |
Why?
|
| Uric Acid | 3 | 2020 | 13 | 0.990 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 22 | 0.970 |
Why?
|
| Dyslipidemias | 2 | 2021 | 16 | 0.930 |
Why?
|
| Child, Preschool | 10 | 2022 | 589 | 0.930 |
Why?
|
| Antihypertensive Agents | 5 | 2019 | 70 | 0.890 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2007 | 15 | 0.870 |
Why?
|
| Alkalosis, Respiratory | 1 | 2023 | 1 | 0.860 |
Why?
|
| Kidney | 3 | 2022 | 154 | 0.860 |
Why?
|
| Acidosis | 1 | 2023 | 5 | 0.850 |
Why?
|
| Renin-Angiotensin System | 2 | 2021 | 5 | 0.850 |
Why?
|
| Glomerular Filtration Rate | 3 | 2019 | 51 | 0.840 |
Why?
|
| Cyclosporine | 1 | 2022 | 11 | 0.820 |
Why?
|
| Urine | 2 | 2019 | 9 | 0.800 |
Why?
|
| Male | 26 | 2022 | 14000 | 0.780 |
Why?
|
| Ureteral Obstruction | 2 | 2019 | 16 | 0.770 |
Why?
|
| Biomarkers | 4 | 2019 | 549 | 0.740 |
Why?
|
| Wasting Syndrome | 1 | 2020 | 1 | 0.730 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2020 | 2 | 0.730 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2020 | 2 | 0.730 |
Why?
|
| Female | 24 | 2022 | 14388 | 0.730 |
Why?
|
| Smoking Cessation | 1 | 2021 | 47 | 0.720 |
Why?
|
| Cerebrum | 1 | 2020 | 11 | 0.720 |
Why?
|
| Hyperuricemia | 2 | 2018 | 3 | 0.710 |
Why?
|
| Polyomavirus | 1 | 2019 | 5 | 0.680 |
Why?
|
| Kidney Pelvis | 1 | 2019 | 14 | 0.680 |
Why?
|
| Risk Factors | 10 | 2021 | 2242 | 0.670 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2019 | 1 | 0.650 |
Why?
|
| Shock | 1 | 2019 | 10 | 0.640 |
Why?
|
| Obesity | 1 | 2021 | 277 | 0.640 |
Why?
|
| Creatinine | 5 | 2021 | 45 | 0.610 |
Why?
|
| Infant | 7 | 2021 | 516 | 0.610 |
Why?
|
| C-Reactive Protein | 2 | 2007 | 99 | 0.560 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 6 | 0.520 |
Why?
|
| Hemofiltration | 1 | 2016 | 8 | 0.520 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 853 | 0.520 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 9 | 0.520 |
Why?
|
| Hypokalemia | 2 | 2008 | 3 | 0.510 |
Why?
|
| Enalapril | 2 | 2019 | 3 | 0.500 |
Why?
|
| Algorithms | 3 | 2012 | 358 | 0.490 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2015 | 4 | 0.490 |
Why?
|
| Sildenafil Citrate | 1 | 2015 | 11 | 0.490 |
Why?
|
| Diabetes Insipidus, Nephrogenic | 1 | 2015 | 3 | 0.490 |
Why?
|
| Adult | 10 | 2023 | 7358 | 0.480 |
Why?
|
| Evidence-Based Medicine | 3 | 2010 | 186 | 0.470 |
Why?
|
| Antimetabolites | 1 | 2013 | 13 | 0.450 |
Why?
|
| Critical Care | 1 | 2016 | 190 | 0.440 |
Why?
|
| Carbonic Anhydrase Inhibitors | 2 | 2019 | 2 | 0.440 |
Why?
|
| Acetazolamide | 2 | 2019 | 3 | 0.440 |
Why?
|
| Pediatrics | 1 | 2013 | 32 | 0.430 |
Why?
|
| Kidney Diseases | 2 | 2006 | 100 | 0.430 |
Why?
|
| Physician's Role | 1 | 2013 | 17 | 0.420 |
Why?
|
| Infant, Newborn | 5 | 2019 | 587 | 0.410 |
Why?
|
| Gout | 1 | 2012 | 7 | 0.410 |
Why?
|
| Fluid Therapy | 3 | 2012 | 31 | 0.400 |
Why?
|
| Behavior Therapy | 2 | 2023 | 81 | 0.380 |
Why?
|
| Disease Progression | 4 | 2019 | 685 | 0.370 |
Why?
|
| HELLP Syndrome | 1 | 2010 | 2 | 0.370 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 6 | 0.370 |
Why?
|
| Placenta | 1 | 2010 | 10 | 0.370 |
Why?
|
| Hypophosphatemia | 1 | 2010 | 1 | 0.360 |
Why?
|
| Critical Illness | 3 | 2023 | 122 | 0.360 |
Why?
|
| Inflammation Mediators | 1 | 2010 | 58 | 0.350 |
Why?
|
| Blood Pressure | 6 | 2020 | 194 | 0.350 |
Why?
|
| Magnesium Deficiency | 1 | 2010 | 1 | 0.350 |
Why?
|
| Gitelman Syndrome | 1 | 2010 | 1 | 0.350 |
Why?
|
| Magnesium | 1 | 2010 | 36 | 0.340 |
Why?
|
| Cytokines | 1 | 2010 | 226 | 0.330 |
Why?
|
| Young Adult | 3 | 2021 | 1852 | 0.320 |
Why?
|
| Glomerulonephritis | 1 | 2009 | 20 | 0.320 |
Why?
|
| Catecholamines | 1 | 2008 | 5 | 0.310 |
Why?
|
| Epilepsy, Tonic-Clonic | 1 | 2008 | 5 | 0.310 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2008 | 2 | 0.310 |
Why?
|
| Acid-Base Imbalance | 1 | 2008 | 2 | 0.310 |
Why?
|
| Transfusion Reaction | 1 | 2008 | 6 | 0.310 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3292 | 0.310 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 24 | 0.280 |
Why?
|
| Cerebellum | 1 | 2007 | 40 | 0.280 |
Why?
|
| Acidosis, Renal Tubular | 1 | 2006 | 2 | 0.270 |
Why?
|
| Premedication | 1 | 2006 | 3 | 0.270 |
Why?
|
| Rett Syndrome | 1 | 2006 | 6 | 0.260 |
Why?
|
| Pregnancy | 2 | 2021 | 309 | 0.260 |
Why?
|
| Transcription Factors | 1 | 2007 | 159 | 0.260 |
Why?
|
| Contrast Media | 1 | 2006 | 60 | 0.260 |
Why?
|
| Nail Diseases | 1 | 2005 | 1 | 0.250 |
Why?
|
| Strontium | 1 | 2005 | 2 | 0.250 |
Why?
|
| Hematuria | 1 | 2005 | 14 | 0.250 |
Why?
|
| Kidney Glomerulus | 1 | 2005 | 47 | 0.240 |
Why?
|
| Autonomic Dysreflexia | 1 | 2004 | 2 | 0.240 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2004 | 5 | 0.240 |
Why?
|
| Down Syndrome | 1 | 2004 | 10 | 0.240 |
Why?
|
| Immunoglobulin G | 1 | 2004 | 87 | 0.230 |
Why?
|
| Diarrhea | 1 | 2003 | 31 | 0.220 |
Why?
|
| Hyperventilation | 1 | 2023 | 1 | 0.220 |
Why?
|
| Bicarbonates | 1 | 2023 | 2 | 0.220 |
Why?
|
| Acid-Base Equilibrium | 1 | 2023 | 6 | 0.220 |
Why?
|
| Pheochromocytoma | 1 | 2003 | 5 | 0.210 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2003 | 9 | 0.210 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 342 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2003 | 11 | 0.210 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2023 | 128 | 0.210 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 24 | 0.210 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2003 | 30 | 0.210 |
Why?
|
| Transplant Recipients | 1 | 2022 | 21 | 0.210 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 9 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 52 | 0.210 |
Why?
|
| Cystinosis | 1 | 2002 | 1 | 0.200 |
Why?
|
| Failure to Thrive | 1 | 2002 | 1 | 0.200 |
Why?
|
| Constipation | 1 | 2002 | 18 | 0.200 |
Why?
|
| Steroids | 1 | 2022 | 23 | 0.200 |
Why?
|
| Rituximab | 1 | 2022 | 50 | 0.200 |
Why?
|
| Body Mass Index | 2 | 2021 | 412 | 0.200 |
Why?
|
| ROC Curve | 2 | 2020 | 132 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 114 | 0.200 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2021 | 7 | 0.200 |
Why?
|
| Colistin | 1 | 2021 | 4 | 0.200 |
Why?
|
| Cholesterol, HDL | 1 | 2021 | 23 | 0.200 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 68 | 0.190 |
Why?
|
| Electrocardiography | 1 | 2022 | 104 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2022 | 122 | 0.190 |
Why?
|
| Renal Dialysis | 1 | 2022 | 107 | 0.190 |
Why?
|
| Body Size | 1 | 2020 | 10 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2019 | 622 | 0.180 |
Why?
|
| Diuretics | 3 | 2019 | 6 | 0.180 |
Why?
|
| Bartter Syndrome | 1 | 2019 | 1 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2010 | 75 | 0.160 |
Why?
|
| Interleukin-18 | 1 | 2019 | 9 | 0.160 |
Why?
|
| Lipocalin-2 | 1 | 2019 | 2 | 0.160 |
Why?
|
| Area Under Curve | 1 | 2019 | 55 | 0.160 |
Why?
|
| Calcium | 1 | 2022 | 368 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 457 | 0.160 |
Why?
|
| Age Factors | 2 | 2013 | 744 | 0.150 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 47 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 170 | 0.150 |
Why?
|
| Radiography | 2 | 2012 | 610 | 0.150 |
Why?
|
| Prevalence | 1 | 2019 | 433 | 0.140 |
Why?
|
| Pharmacokinetics | 1 | 2016 | 3 | 0.130 |
Why?
|
| Iran | 3 | 2020 | 32 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 2016 | 22 | 0.130 |
Why?
|
| Risk | 1 | 2016 | 199 | 0.120 |
Why?
|
| Cyclic GMP | 1 | 2015 | 5 | 0.120 |
Why?
|
| Aquaporin 2 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 17 | 0.120 |
Why?
|
| Urinalysis | 1 | 2015 | 8 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2013 | 38 | 0.110 |
Why?
|
| Insurance, Health | 1 | 2013 | 18 | 0.100 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Urethral Obstruction | 1 | 2012 | 1 | 0.100 |
Why?
|
| Syndrome | 2 | 2003 | 73 | 0.100 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2012 | 5 | 0.100 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 42 | 0.100 |
Why?
|
| Urethra | 1 | 2012 | 14 | 0.100 |
Why?
|
| Urinary Bladder | 1 | 2012 | 19 | 0.100 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2012 | 27 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2012 | 64 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2012 | 92 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 140 | 0.100 |
Why?
|
| Spironolactone | 2 | 2019 | 2 | 0.090 |
Why?
|
| Fetal Blood | 1 | 2010 | 13 | 0.090 |
Why?
|
| Patient Selection | 1 | 2012 | 193 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 53 | 0.090 |
Why?
|
| Life Style | 1 | 2012 | 186 | 0.090 |
Why?
|
| Hydrocortisone | 1 | 2010 | 38 | 0.090 |
Why?
|
| Calcitriol | 1 | 2010 | 4 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2010 | 72 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 156 | 0.090 |
Why?
|
| Vitamins | 1 | 2010 | 19 | 0.090 |
Why?
|
| Phosphates | 1 | 2010 | 18 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2012 | 132 | 0.090 |
Why?
|
| Problem Solving | 1 | 2010 | 46 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 185 | 0.080 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 34 | 0.080 |
Why?
|
| Furosemide | 1 | 2009 | 1 | 0.080 |
Why?
|
| Hyperparathyroidism | 1 | 2009 | 6 | 0.080 |
Why?
|
| Renin | 1 | 2008 | 1 | 0.080 |
Why?
|
| Electroretinography | 1 | 2007 | 1 | 0.070 |
Why?
|
| Kidney Diseases, Cystic | 1 | 2007 | 2 | 0.070 |
Why?
|
| Blindness | 1 | 2007 | 12 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 104 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2007 | 252 | 0.070 |
Why?
|
| Neoplasms | 1 | 2009 | 219 | 0.070 |
Why?
|
| Water Supply | 1 | 2005 | 4 | 0.060 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2005 | 8 | 0.060 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2004 | 4 | 0.060 |
Why?
|
| Labetalol | 1 | 2004 | 5 | 0.060 |
Why?
|
| Glomerular Mesangium | 1 | 2004 | 3 | 0.060 |
Why?
|
| Drainage | 1 | 2004 | 46 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2004 | 37 | 0.060 |
Why?
|
| Dehydration | 1 | 2003 | 3 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2009 | 1821 | 0.050 |
Why?
|
| Microcephaly | 1 | 2003 | 1 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2003 | 1 | 0.050 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2003 | 3 | 0.050 |
Why?
|
| von Hippel-Lindau Disease | 1 | 2003 | 3 | 0.050 |
Why?
|
| Hearing Loss, Bilateral | 1 | 2003 | 3 | 0.050 |
Why?
|
| Ligases | 1 | 2003 | 8 | 0.050 |
Why?
|
| Serine | 1 | 2003 | 8 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 10 | 0.050 |
Why?
|
| Cryptorchidism | 1 | 2003 | 4 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 18 | 0.050 |
Why?
|
| Mutation, Missense | 1 | 2003 | 21 | 0.050 |
Why?
|
| Glycine | 1 | 2003 | 12 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2003 | 26 | 0.050 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 2002 | 2 | 0.050 |
Why?
|
| Amiloride | 1 | 2002 | 4 | 0.050 |
Why?
|
| Kidney Function Tests | 1 | 2002 | 21 | 0.050 |
Why?
|
| Electrolytes | 1 | 2002 | 13 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 49 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2002 | 40 | 0.050 |
Why?
|
| Random Allocation | 1 | 2002 | 119 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 1140 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2020 | 12 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2020 | 5 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 415 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2020 | 31 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2002 | 222 | 0.040 |
Why?
|
| Body Height | 1 | 2020 | 33 | 0.040 |
Why?
|
| Indomethacin | 1 | 2019 | 3 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2009 | 3294 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2019 | 26 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 338 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 442 | 0.040 |
Why?
|